Abstract
N and C are two approved agents after a prior TKI in mRCC pts. However, the optimal sequence, CN or NC, is still unknown. The superiority of C over everolimus in pts with prior anti-PD-1 (HR 0.22) in the METEOR trial suggests a sensitizing role of N. We conducted the CABIR study to identify the optimal sequence between CN and NC after one prior TKI.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
